155 related articles for article (PubMed ID: 31277827)
1. Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?
Pouwels XGLV; Grutters JPC; Bindels J; Ramaekers BLT; Joore MA
Value Health; 2019 Jul; 22(7):799-807. PubMed ID: 31277827
[TBL] [Abstract][Full Text] [Related]
2. Coverage with Evidence Development: applications and issues.
Trueman P; Grainger DL; Downs KE
Int J Technol Assess Health Care; 2010 Jan; 26(1):79-85. PubMed ID: 20059784
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models.
Grimm SE; Pouwels X; Ramaekers BLT; Wijnen B; Knies S; Grutters J; Joore MA
Pharmacoeconomics; 2020 Feb; 38(2):205-216. PubMed ID: 31709496
[TBL] [Abstract][Full Text] [Related]
4. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.
Stafinski T; McCabe CJ; Menon D
Pharmacoeconomics; 2010; 28(2):113-42. PubMed ID: 20085389
[TBL] [Abstract][Full Text] [Related]
5. Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time.
Sandmann FG; Franken MG; Steenhoek A; Koopmanschap MA
Health Policy; 2013 Oct; 112(3):285-96. PubMed ID: 23628483
[TBL] [Abstract][Full Text] [Related]
6. Coverage with evidence development: the Ontario experience.
Levin L; Goeree R; Levine M; Krahn M; Easty T; Brown A; Henry D
Int J Technol Assess Health Care; 2011 Apr; 27(2):159-68. PubMed ID: 21473814
[TBL] [Abstract][Full Text] [Related]
7. Coverage with evidence development for medical devices in Europe: Can practice meet theory?
Drummond M; Federici C; Reckers-Droog V; Torbica A; Blankart CR; Ciani O; Kaló Z; Kovács S; Brouwer W
Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):179-194. PubMed ID: 35220644
[TBL] [Abstract][Full Text] [Related]
8. Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries.
Kovács S; Kaló Z; Daubner-Bendes R; Kolasa K; Hren R; Tesar T; Reckers-Droog V; Brouwer W; Federici C; Drummond M; Zemplényi AT
Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):195-206. PubMed ID: 35322478
[TBL] [Abstract][Full Text] [Related]
9. Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives.
Bindels J; Ramaekers B; Ramos IC; Mohseninejad L; Knies S; Grutters J; Postma M; Al M; Feenstra T; Joore M
Pharmacoeconomics; 2016 Mar; 34(3):315-22. PubMed ID: 26578403
[TBL] [Abstract][Full Text] [Related]
10. Health technology assessment in Switzerland: a descriptive analysis of "Coverage with Evidence Development" decisions from 1996 to 2013.
Brügger U; Horisberger B; Ruckstuhl A; Plessow R; Eichler K; Gratwohl A
BMJ Open; 2015 Mar; 5(3):e007021. PubMed ID: 25818273
[TBL] [Abstract][Full Text] [Related]
11. Conditional Financing of Drugs in the Netherlands: Past, Present, and Future-Results From Stakeholder Interviews.
Makady A; van Acker S; Nijmeijer H; de Boer A; Hillege H; Klungel O; Goettsch W
Value Health; 2019 Apr; 22(4):399-407. PubMed ID: 30975390
[TBL] [Abstract][Full Text] [Related]
12. Coverage with evidence development: an examination of conceptual and policy issues.
Hutton J; Trueman P; Henshall C
Int J Technol Assess Health Care; 2007; 23(4):425-32. PubMed ID: 17937829
[TBL] [Abstract][Full Text] [Related]
13. Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges.
Federici C; Reckers-Droog V; Ciani O; Dams F; Grigore B; Kaló Z; Kovács S; Shatrov K; Brouwer W; Drummond M
Eur J Health Econ; 2021 Nov; 22(8):1253-1273. PubMed ID: 34117987
[TBL] [Abstract][Full Text] [Related]
14. Determining the impact of modeling additional sources of uncertainty in value-of-information analysis.
Ramos IC; P M H M; Mölken RV; Al MJ
Value Health; 2015 Jan; 18(1):100-9. PubMed ID: 25595240
[TBL] [Abstract][Full Text] [Related]
15. Implementing managed entry agreements in practice: The Dutch reality check.
Makady A; van Veelen A; de Boer A; Hillege H; Klungel OH; Goettsch W
Health Policy; 2019 Mar; 123(3):267-274. PubMed ID: 30316540
[TBL] [Abstract][Full Text] [Related]
16. Role of health insurance in financing vaccinations for children and adolescents in the United States.
Shen AK; Hunsaker J; Gazmararian JA; Lindley MC; Birkhead GS
Pediatrics; 2009 Dec; 124 Suppl 5():S522-31. PubMed ID: 19948584
[TBL] [Abstract][Full Text] [Related]
17. Access with evidence development schemes: a framework for description and evaluation.
McCabe CJ; Stafinski T; Edlin R; Menon D;
Pharmacoeconomics; 2010; 28(2):143-52. PubMed ID: 20085390
[TBL] [Abstract][Full Text] [Related]
18. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis.
Fischer KE; Rogowski WH; Leidl R; Stollenwerk B
Health Policy; 2013 Oct; 112(3):187-96. PubMed ID: 23664301
[TBL] [Abstract][Full Text] [Related]
19. Coverage with evidence development for pharmaceuticals: a policy in evolution?
Lexchin J
Int J Health Serv; 2011; 41(2):337-54. PubMed ID: 21563627
[TBL] [Abstract][Full Text] [Related]
20. Developing a patient-directed policy framework for managing orphan and ultra-orphan drugs throughout their lifecycle.
Menon D; Stafinski T; Dunn A; Wong-Rieger D
Patient; 2015 Feb; 8(1):103-17. PubMed ID: 25559762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
